

Rapid Dose Announces Results of Annual General and Special Meeting of Shareholders

BURLINGTON, ON, CANADA, August 3, 2023 /EINPresswire.com/ -- [Rapid Dose Therapeutics Corp.](#) ("RDT" or the "Company") (CSE: DOSE) is pleased to announce the voting results from its annual general and special meeting of shareholders (the "Meeting") held on August 1, 2023.

All matters presented to the Meeting were approved by the Company's shareholders as more particularly set forth in the Company's management information circular dated June 30, 2023 (the "Circular") and as set forth below, other than the special resolution to create a new class of shares to be designated as 'preferred shares':

- the election of six nominees to the board of directors as proposed by the Company in the Circular, being incumbent directors Mark Upsdell, Peter Thilo Hasler and John McKimm and new directors, Marisa Cornacchia, Andrew Duckman and Christine Hrudka;
 - the re-appointment of SRCO Professional Corporation, Chartered Professional Accountants, as auditor of the Company;
 - the re-approval of the Company's stock option plan;
 - the ratification of the Company's advance notice by-law;
 - the special resolution to consolidate the Company's shares on a one (1) for up to ten (10) basis;
- and
- the ratification of deficiencies relating to previous annual general meetings.

The consolidation resolution provides that the board of directors of the Company (the "Board"), in its discretion, may determine whether or not to proceed with the share consolidation. Accordingly, if the Board determines to proceed with the share consolidation, then the Company will issue a further press release advising shareholders of the timing, details and effective date of such consolidation.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.

Contacts:

RDT Investor Contact:

Mark Upsdell, CEO

mupsdell@rapid-dose.com

416-477-1052

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

MARK UPSDELL

Rapid Dose Therapeutics

+1 416-477-1052

mupsdell@rapid-dose.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/648055254>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.